Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01587196 · ClinicalTrials.gov registry record · Phase 2

CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery

A Phase 2 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 2
Development phase
72
Enrollment target

NCT01587196: Completed Phase 2 study, sponsored by University of Pennsylvania.

NCT01587196 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01587196, a Phase 2 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 2
Development phase
72 participants
Enrollment target

Study Summary

The proposed project will use fMRI and specific probes of reward and inhibition as biomarkers predicting drug use during and after treatment in 72 subjects addicted to prescription opioids/medications. Subjects will be scanned before, during, and after 12 weeks of active medication. The brain fMRI measures will be correlated with the primary clinical outcome of drug use (by urine drug screen) during the treatment and follow-up phase.

Interventions

  • DRUG Vivitrol

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2012-01
Est. Completion 2021-01-01
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT01587196

The ClinicalTrials.gov registry entry for NCT01587196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Vivitrol is the first listed.

NCT01587196 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01587196 about?

NCT01587196 is a clinical study titled "CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery". The proposed project will use fMRI and specific probes of reward and inhibition as biomarkers predicting drug use during and after treatment in 72 subjects addicted to prescription opioids/medications. Subjects will be scanned before, during, and after 12 weeks of active medication. The brain fMRI m...

What is the current status of trial NCT01587196?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2012-01. Estimated completion is 2021-01-01.

What interventions are being tested in trial NCT01587196?

The interventions under investigation include: Vivitrol (DRUG).

Who is sponsoring clinical trial NCT01587196?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.